JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

Search

Incyte Corp

Fermé

SecteurSoins de santé

70.33 -0.38

Résumé

Variation du prix de l'action

24h

Actuel

Min

70.03

Max

70.63

Chiffres clés

By Trading Economics

Revenu

-43M

158M

Ventes

-126M

1.1B

P/E

Moyenne du Secteur

336.9

38.156

BPA

1.16

Marge bénéficiaire

15.025

Employés

2,617

EBITDA

-80M

257M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+13.39% upside

Dividendes

By Dow Jones

Prochains Résultats

29 juil. 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-3B

13B

Ouverture précédente

70.71

Clôture précédente

70.33

Sentiment de l'Actualité

By Acuity

83%

17%

353 / 375 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Bullish Evidence

Incyte Corp Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

25 juil. 2025, 17:53 UTC

Principaux Mouvements du Marché

Genworth Shares Rise On UK Court Ruling That Could Lead to $750 Million Windfall

25 juil. 2025, 15:58 UTC

Résultats
Principaux Mouvements du Marché

Aon Shares Rise After 2Q Earnings Beat

25 juil. 2025, 15:08 UTC

Principaux Mouvements du Marché

AST SpaceMobile Shares Slide After Convertible Notes, Stock Offerings

25 juil. 2025, 21:40 UTC

Market Talk

Starbucks' Spending Hikes Are Misdirected -- Market Talk

25 juil. 2025, 21:23 UTC

Market Talk

Honeywell's Growth Seen Holding Up Despite Recent Headwinds -- Market Talk

25 juil. 2025, 20:40 UTC

Résultats

Tesla Stock Is Rising. Robo-taxi Trumps a Lack of New Models. -- Barrons.com

25 juil. 2025, 20:10 UTC

Résultats

These Stocks Moved the Most Today: Intel, Centene, Charter, Newmont, Deckers, Boston Beer, Tesla, and More -- Barrons.com

25 juil. 2025, 19:56 UTC

Résultats

Correction to Why Bargain Hunters Are Flocking to 'Bin Stores' -- Barrons.com on July 20

25 juil. 2025, 19:14 UTC

Market Talk

Oil Futures Post Back-to-Back Weekly Losses -- Market Talk

25 juil. 2025, 19:10 UTC

Market Talk

U.S. Natural Gas Futures Appear to Stabilize -- Market Talk

25 juil. 2025, 19:01 UTC

Résultats

These Stocks Are Moving the Most Today: Intel, Centene, Charter, Newmont, Deckers, Boston Beer, Tesla, and More -- Barrons.com

25 juil. 2025, 18:45 UTC

Market Talk

Gold Ends Down Week on Lower Note -- Market Talk

25 juil. 2025, 18:35 UTC

Acquisitions, Fusions, Rachats

Sale Could Fetch Around $1B, Sources Say -- WSJ

25 juil. 2025, 18:35 UTC

Acquisitions, Fusions, Rachats

LVMH in Talks to Sell Marc Jacobs -- WSJ

25 juil. 2025, 18:35 UTC

Acquisitions, Fusions, Rachats

Suitors for Marc Jacobs Include Authentic, Bluestar Alliance and WHP Global, Sources Say -- WSJ

25 juil. 2025, 18:35 UTC

Acquisitions, Fusions, Rachats

LVMH Exploring Sale of Fashion Brand Marc Jacobs, Sources Say -- WSJ

25 juil. 2025, 17:38 UTC

Principaux Mouvements du Marché

Genworth Shares Rise On UK Court Ruling That Could Lead to $750M Windfall

25 juil. 2025, 17:26 UTC

Market Talk

U.S. Oil Rig Count Extends Decline -- Market Talk

25 juil. 2025, 17:13 UTC

Résultats

Tesla Stock Is Rising. Robo-taxi Trumps a Lack of New Models. -- Barrons.com

25 juil. 2025, 16:46 UTC

Résultats

Volkswagen Teases Made-in-America Audis, Porsches After $1.5 Billion Tariff Hit -- 2nd Update

25 juil. 2025, 16:45 UTC

Résultats

Apple Earnings Are Next Week. Why This Analyst Says Be Cautious. -- Barrons.com

25 juil. 2025, 16:27 UTC

Résultats

These Stocks Are Moving the Most Today: Intel, Centene, Charter, Newmont, Deckers, Boston Beer, Tesla, and More -- Barrons.com

25 juil. 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

25 juil. 2025, 16:02 UTC

Résultats
Acquisitions, Fusions, Rachats

Berkshire Stock Is Losing Its Buffett Premium. Now Is the Time to Buy. -- Barrons.com

25 juil. 2025, 15:34 UTC

Résultats

Intel's Harsh Reality Nullifies Tariff Boost -- WSJ

25 juil. 2025, 15:06 UTC

Market Talk

Base Metal Prices Fall on Stronger U.S. Dollar -- Market Talk

25 juil. 2025, 15:05 UTC

Résultats

These Stocks Are Moving the Most Today: Intel, Centene, Charter, Newmont, Deckers, Boston Beer, Comfort Systems, and More -- Barrons.com

25 juil. 2025, 14:45 UTC

Market Talk

Oil Rangebound Amid U.S.-EU Trade Uncertainty -- Market Talk

25 juil. 2025, 14:44 UTC

Market Talk

Gold Futures Set to End Week Lower on Easing Trade War Concerns -- Market Talk

25 juil. 2025, 14:36 UTC

Market Talk
Résultats

Phillips 66 CEO Says California Administration Supports of LA Plant Closure -- Market Talk

Comparaison

Variation de prix

Incyte Corp prévision

Objectif de Prix

By TipRanks

13.39% hausse

Prévisions sur 12 Mois

Moyen 79.6 USD  13.39%

Haut 107 USD

Bas 52 USD

Basé sur 17 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

17 ratings

7

Achat

9

Maintien

1

Vente

Score Technique

By Trading Central

59.52 / 62.66Support & Résistance

Court Terme

Bullish Evidence

Moyen Terme

Bearish Evidence

Long Terme

Bearish Evidence

Sentiment

By Acuity

353 / 375Classement par Soins de santé

Sentiment de l'Actualité

Très Fortes Indications Baissières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation